ID   RN5A_HUMAN              Reviewed;         741 AA.
AC   Q05823;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   02-NOV-2010, entry version 103.
DE   RecName: Full=2-5A-dependent ribonuclease;
DE            Short=2-5A-dependent RNase;
DE            EC=3.1.26.-;
DE   AltName: Full=Ribonuclease 4;
DE   AltName: Full=Ribonuclease L;
DE            Short=RNase L;
GN   Name=RNASEL; Synonyms=RNS4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND MUTAGENESIS OF LYS-240 AND
RP   LYS-274.
RC   TISSUE=Kidney;
RX   MEDLINE=93201598; PubMed=7680958; DOI=10.1016/0092-8674(93)90403-D;
RA   Zhou A., Hassel B.A., Silverman R.H.;
RT   "Expression cloning of 2-5A-dependent RNAase: a uniquely regulated
RT   mediator of interferon action.";
RL   Cell 72:753-765(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   MEDLINE=20515260; PubMed=11063255; DOI=10.1007/s003350010194;
RA   Zhou A., Nie H., Silverman R.H.;
RT   "Analysis and origins of the human and mouse RNase L genes: mediators
RT   of interferon action.";
RL   Mamm. Genome 11:989-992(2000).
RN   [3]
RP   CHARACTERIZATION OF RNASEL ACTIVITY.
RX   MEDLINE=94245737; PubMed=7514601;
RA   Dong B., Xu L., Zhou A., Hassel B.A., Lee X., Torrence P.F.,
RA   Silverman R.H.;
RT   "Intrinsic molecular activities of the interferon-induced 2-5A-
RT   dependent RNase.";
RL   J. Biol. Chem. 269:14153-14158(1994).
RN   [4]
RP   INTERACTION WITH ABCE1.
RX   MEDLINE=95286622; PubMed=7539425; DOI=10.1074/jbc.270.22.13308;
RA   Bisbal C., Martinand C., Silhol M., Lebleu B., Salehzada T.;
RT   "Cloning and characterization of a RNase L inhibitor. A new component
RT   of the interferon-regulated 2-5A pathway.";
RL   J. Biol. Chem. 270:13308-13317(1995).
RN   [5]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   MEDLINE=21611192; PubMed=11585831; DOI=10.1074/jbc.M107482200;
RA   Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B.,
RA   Salehzada T.;
RT   "The 2-5A/RNase L/RNase L inhibitor (RNI) pathway regulates
RT   mitochondrial mRNAs stability in interferon alpha-treated H9 cells.";
RL   J. Biol. Chem. 276:48473-48482(2001).
RN   [6]
RP   ERRATUM.
RA   Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B.,
RA   Salehzada T.;
RL   J. Biol. Chem. 277:13354-13354(2002).
RN   [7]
RP   REVIEW.
RX   MEDLINE=99073516; PubMed=9856285; DOI=10.1016/S0753-3322(99)80006-7;
RA   Castelli J., Wood K.A., Youle R.J.;
RT   "The 2-5A system in viral infection and apoptosis.";
RL   Biomed. Pharmacother. 52:386-390(1998).
RN   [8]
RP   MUTAGENESIS OF LYS-392.
RX   MEDLINE=99081839; PubMed=9862963; DOI=10.1093/nar/27.2.439;
RA   Dong B., Silverman R.H.;
RT   "Alternative function of a protein kinase homology domain in 2', 5'-
RT   oligoadenylate dependent RNase L.";
RL   Nucleic Acids Res. 27:439-445(1999).
RN   [9]
RP   MUTAGENESIS OF HIS-583; PRO-584; TRP-632; ASP-661; ARG-667 AND
RP   HIS-672.
RX   MEDLINE=21230542; PubMed=11333017; DOI=10.1017/S1355838201002230;
RA   Dong B., Niwa M., Walter P., Silverman R.H.;
RT   "Basis for regulated RNA cleavage by functional analysis of RNase L
RT   and Ire1p.";
RL   RNA 7:361-373(2001).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-684, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 21-305 IN COMPLEX WITH THE
RP   ACTIVATOR 2-5A.
RX   PubMed=15385955; DOI=10.1038/sj.emboj.7600420;
RA   Tanaka N., Nakanishi M., Kusakabe Y., Goto Y., Kitade Y.,
RA   Nakamura K.T.;
RT   "Structural basis for recognition of 2',5'-linked oligoadenylates by
RT   human ribonuclease L.";
RL   EMBO J. 23:3929-3938(2004).
RN   [12]
RP   VARIANTS SER-59; PHE-406; GLN-462 AND GLU-541.
RX   MEDLINE=21947464; PubMed=11941539; DOI=10.1086/340450;
RA   Roekman A., Ikonen T., Seppaelae E.H., Nupponen N., Autio V.,
RA   Mononen N., Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P.,
RA   Koivisto P.A., Tammela T.L.J., Kallioniemi O.-P., Schleutker J.;
RT   "Germline alterations of the RNASEL gene, a candidate HPC1 gene at
RT   1q25, in patients and families with prostate cancer.";
RL   Am. J. Hum. Genet. 70:1299-1304(2002).
RN   [13]
RP   VARIANTS SER-59; GLN-462 AND GLU-541.
RX   MEDLINE=21676832; PubMed=11799394; DOI=10.1038/ng823;
RA   Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J.,
RA   Faruque M., Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P.,
RA   Makalowska I., Baffoe-Bonnie A., Faith D., Smith J., Stephan D.,
RA   Wiley K., Brownstein M., Gildea D., Kelly B., Jenkins R.,
RA   Hostetter G., Matikainen M., Schleutker J., Klinger K., Connors T.,
RA   Xiang Y., Wang Z., De Marzo A., Papadopoulos N., Kallioniemi O.-P.,
RA   Burk R., Meyers D., Groenberg H., Meltzer P., Silverman R.,
RA   Bailey-Wilson J., Walsh P., Isaacs W., Trent J.;
RT   "Germline mutations in the ribonuclease L gene in families showing
RT   linkage with HPC1.";
RL   Nat. Genet. 30:181-184(2002).
RN   [14]
RP   CHARACTERIZATION OF VARIANTS GLN-462 AND GLU-541.
RX   MEDLINE=22345000; PubMed=12415269; DOI=10.1038/ng1021;
RA   Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M.,
RA   Klein E.A., Catalona W.J., Nupponen N., Carpten J.D., Trent J.M.,
RA   Silverman R.H., Witte J.S.;
RT   "RNASEL Arg462Gln variant is implicated in up to 13% of prostate
RT   cancer cases.";
RL   Nat. Genet. 32:581-583(2002).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-97; THR-289; GLN-462; GLU-541 AND
RP   HIS-592.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Endoribonuclease that functions in the interferon (IFN)
CC       antiviral response. In INF treated and virus infected cells,
CC       RNASEL probably mediates its antiviral effects through a
CC       combination of direct cleavage of single-stranded viral RNAs,
CC       inhibition of protein synthesis through the degradation of rRNA,
CC       induction of apoptosis, and induction of other antiviral genes.
CC       RNASEL mediated apoptosis is the result of a JNK-dependent stress-
CC       response pathway leading to cytochrome c release from mitochondria
CC       and caspase-dependent apoptosis. Therefore, activation of RNASEL
CC       could lead to elimination of virus infected cells under some
CC       circumstances. Might play a central role in the regulation of
CC       mRNA. turnover.
CC   -!- CATALYTIC ACTIVITY: Cleaves 3' of UpNp dimers, with preference for
CC       UU and UA sequences, to sets of discrete products ranging from
CC       between 4 and 22 nucleotides in length.
CC   -!- COFACTOR: Manganese or magnesium. Required for optimal RNA
CC       cleavage rates.
CC   -!- ENZYME REGULATION: After binding to 2-5A (5'-phosphorylated 2',5'-
CC       linked oligoadenylates) the homodimerization and subsequent
CC       activation occurs. Inhibited by RNASEL inhibitor ABCE1/RLI, a
CC       cytoplasmic member of the ATP-binding cassette (ABC) transporter
CC       family.
CC   -!- SUBUNIT: Monomer (inactive form) or homodimer. Interacts with
CC       ABCE1; this interaction inhibits the RNASEL.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Mitochondrion.
CC   -!- TISSUE SPECIFICITY: Highly expressed in spleen and thymus followed
CC       by prostate, testis, uterus, small intestine, colon and peripheral
CC       blood leukocytes.
CC   -!- INDUCTION: By interferons. Virus replication in higher vertebrates
CC       is restrained by IFNs that cause cells to transcribe genes
CC       encoding antiviral proteins, such as 2'-5' oligoadenylate
CC       synthetases (OASs). oligoadenylate synthetase is stimulated by
CC       dsRNA to produce 5'-phosphorylated, 2'-5'-linked oligoadenylates
CC       (2-5A), whose function is to activate RNASEL.
CC   -!- DOMAIN: The nine ankyrin repeats also called 2-5A sensor
CC       constitute the N-terminus 2-5A binding domain.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive. It allows the homodimerization.
CC   -!- DOMAIN: The ribonuclease domain is located in the C-terminus. A
CC       single active nuclease domain in a dimer is sufficient for
CC       ribonuclease activity (By similarity).
CC   -!- DISEASE: Defects in RNASEL are a cause of susceptibility to
CC       prostate cancer hereditary type 1 (HPC1) [MIM:601518]. It is a
CC       condition associated with familial predisposition to cancer of the
CC       prostate. Most prostate cancers are adenocarcinomas that develop
CC       in the acini of the prostatic ducts. Other rare histopathologic
CC       types of prostate cancer that occur in approximately 5% of
CC       patients include small cell carcinoma, mucinous carcinoma,
CC       prostatic ductal carcinoma, transitional cell carcinoma, squamous
CC       cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma
CC       (basaloid), signet-ring cell carcinoma and neuroendocrine
CC       carcinoma.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily.
CC   -!- SIMILARITY: Contains 9 ANK repeats.
CC   -!- SIMILARITY: Contains 1 KEN domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L10381; AAA18032.1; -; Genomic_DNA.
DR   IPI; IPI00015864; -.
DR   PIR; A45771; A45771.
DR   RefSeq; NP_066956.1; -.
DR   UniGene; Hs.518545; -.
DR   PDB; 1WDY; X-ray; 1.80 A; A=21-305.
DR   PDBsum; 1WDY; -.
DR   ProteinModelPortal; Q05823; -.
DR   SMR; Q05823; 358-714.
DR   STRING; Q05823; -.
DR   PhosphoSite; Q05823; -.
DR   PeptideAtlas; Q05823; -.
DR   PRIDE; Q05823; -.
DR   Ensembl; ENST00000367559; ENSP00000356530; ENSG00000135828.
DR   Ensembl; ENST00000444138; ENSP00000411147; ENSG00000135828.
DR   GeneID; 6041; -.
DR   KEGG; hsa:6041; -.
DR   UCSC; uc001gpj.1; human.
DR   CTD; 6041; -.
DR   GeneCards; GC01M182542; -.
DR   H-InvDB; HIX0028845; -.
DR   HGNC; HGNC:10050; RNASEL.
DR   HPA; CAB010906; -.
DR   HPA; HPA002633; -.
DR   MIM; 176807; phenotype.
DR   MIM; 180435; gene.
DR   MIM; 601518; phenotype.
DR   Orphanet; 1331; Familial prostate cancer.
DR   PharmGKB; PA34418; -.
DR   eggNOG; prNOG04117; -.
DR   HOGENOM; HBG280468; -.
DR   HOVERGEN; HBG012673; -.
DR   InParanoid; Q05823; -.
DR   OMA; NMGRNAL; -.
DR   OrthoDB; EOG9X9B3Q; -.
DR   PhylomeDB; Q05823; -.
DR   NextBio; 23543; -.
DR   PMAP-CutDB; Q05823; -.
DR   ArrayExpress; Q05823; -.
DR   Bgee; Q05823; -.
DR   CleanEx; HS_RNASEL; -.
DR   Genevestigator; Q05823; -.
DR   GermOnline; ENSG00000135828; Homo sapiens.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016891; F:endoribonuclease activity, producing 5'-pho...; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0006397; P:mRNA processing; IEA:InterPro.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; NAS:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IEA:UniProtKB-KW.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR010513; KEN_RNase_activator.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR006567; PUG-dom.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   Gene3D; G3DSA:1.25.40.20; ANK; 1.
DR   Pfam; PF00023; Ank; 4.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF06479; Ribonuc_2-5A; 1.
DR   SMART; SM00248; ANK; 8.
DR   SMART; SM00580; PUG; 1.
DR   SUPFAM; SSF48403; ANK; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 6.
DR   PROSITE; PS51392; KEN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ANK repeat; Antiviral defense; ATP-binding;
KW   Complete proteome; Cytoplasm; Endonuclease; Hydrolase; Metal-binding;
KW   Mitochondrion; Nuclease; Nucleotide-binding; Polymorphism; Repeat;
KW   RNA-binding; Zinc; Zinc-finger.
FT   CHAIN         1    741       2-5A-dependent ribonuclease.
FT                                /FTId=PRO_0000067051.
FT   REPEAT       24     53       ANK 1.
FT   REPEAT       58     87       ANK 2.
FT   REPEAT       91    120       ANK 3.
FT   REPEAT      124    153       ANK 4.
FT   REPEAT      167    197       ANK 5.
FT   REPEAT      201    234       ANK 6.
FT   REPEAT      238    268       ANK 7.
FT   REPEAT      272    301       ANK 8.
FT   REPEAT      303    329       ANK 9.
FT   DOMAIN      365    586       Protein kinase.
FT   DOMAIN      589    723       KEN.
FT   ZN_FING     395    444       C6-type; atypical.
FT   REGION      229    242       2-5A binding (P-loop) 1.
FT   REGION      253    275       2-5A binding (P-loop) 2.
FT   MOD_RES     684    684       N6-acetyllysine.
FT   VARIANT      59     59       G -> S.
FT                                /FTId=VAR_013509.
FT   VARIANT      97     97       I -> L (in dbSNP:rs56250729).
FT                                /FTId=VAR_042358.
FT   VARIANT     289    289       A -> T (in dbSNP:rs35553278).
FT                                /FTId=VAR_042359.
FT   VARIANT     406    406       S -> F.
FT                                /FTId=VAR_013510.
FT   VARIANT     462    462       R -> Q (risk factor for prostate cancer;
FT                                reduced enzymatic activity;
FT                                dbSNP:rs486907).
FT                                /FTId=VAR_012056.
FT   VARIANT     541    541       D -> E (no change in enzymatic activity;
FT                                dbSNP:rs627928).
FT                                /FTId=VAR_012057.
FT   VARIANT     592    592       R -> H (in dbSNP:rs35896902).
FT                                /FTId=VAR_042360.
FT   MUTAGEN     240    240       K->N: Reduced 2-5A binding activity;
FT                                almost complete loss of 2-5A binding
FT                                activity; when associated with N-274.
FT   MUTAGEN     274    274       K->N: Reduced 2-5A binding activity;
FT                                almost complete loss of 2-5A binding
FT                                activity; when associated with N-240.
FT   MUTAGEN     392    392       K->R: Complete loss of enzymatic activity
FT                                and enzyme dimerization. No change in
FT                                binding to 2-5A and RNA.
FT   MUTAGEN     583    583       H->A: No change in enzymatic activity.
FT   MUTAGEN     584    584       P->A: No change in enzymatic activity.
FT   MUTAGEN     632    632       W->A: No change in enzymatic activity.
FT   MUTAGEN     661    661       D->A: Complete loss of enzymatic
FT                                activity.
FT   MUTAGEN     667    667       R->A: Complete loss of enzymatic
FT                                activity. No change in 2-5A binding and
FT                                enzyme dimerization.
FT   MUTAGEN     672    672       H->A: Complete loss of enzymatic
FT                                activity. No change in 2-5A binding
FT                                activity and enzyme dimerization.
FT   HELIX        22     34
FT   HELIX        38     46
FT   TURN         56     58
FT   HELIX        62     68
FT   HELIX        72     80
FT   HELIX        95    102
FT   HELIX       105    113
FT   HELIX       128    134
FT   HELIX       138    146
FT   HELIX       159    163
FT   HELIX       171    178
FT   HELIX       181    189
FT   HELIX       205    211
FT   TURN        215    217
FT   HELIX       218    227
FT   HELIX       242    248
FT   HELIX       252    260
FT   STRAND      261    263
FT   HELIX       276    282
FT   HELIX       286    295
SQ   SEQUENCE   741 AA;  83533 MW;  91385EA307E3CE1D CRC64;
     MESRDHNNPQ EGPTSSSGRR AAVEDNHLLI KAVQNEDVDL VQQLLEGGAN VNFQEEEGGW
     TPLHNAVQMS REDIVELLLR HGADPVLRKK NGATPFILAA IAGSVKLLKL FLSKGADVNE
     CDFYGFTAFM EAAVYGKVKA LKFLYKRGAN VNLRRKTKED QERLRKGGAT ALMDAAEKGH
     VEVLKILLDE MGADVNACDN MGRNALIHAL LSSDDSDVEA ITHLLLDHGA DVNVRGERGK
     TPLILAVEKK HLGLVQRLLE QEHIEINDTD SDGKTALLLA VELKLKKIAE LLCKRGASTD
     CGDLVMTARR NYDHSLVKVL LSHGAKEDFH PPAEDWKPQS SHWGAALKDL HRIYRPMIGK
     LKFFIDEKYK IADTSEGGIY LGFYEKQEVA VKTFCEGSPR AQREVSCLQS SRENSHLVTF
     YGSESHRGHL FVCVTLCEQT LEACLDVHRG EDVENEEDEF ARNVLSSIFK AVQELHLSCG
     YTHQDLQPQN ILIDSKKAAH LADFDKSIKW AGDPQEVKRD LEDLGRLVLY VVKKGSISFE
     DLKAQSNEEV VQLSPDEETK DLIHRLFHPG EHVRDCLSDL LGHPFFWTWE SRYRTLRNVG
     NESDIKTRKS ESEILRLLQP GPSEHSKSFD KWTTKINECV MKKMNKFYEK RGNFYQNTVG
     DLLKFIRNLG EHIDEEKHKK MKLKIGDPSL YFQKTFPDLV IYVYTKLQNT EYRKHFPQTH
     SPNKPQCDGA GGASGLASPG C
//
